For decades, the pharmaceutical industry has invested heavily in scientific innovation, regulatory rigor, clinical development, manufacturing quality, and commercial excellence. Yet one of the most important links between innovation and patient impact has remained inconsistently standardized across the industry: the capabilities of the Medical Affairs workforce, particularly Medical Science Liaisons.
Medical Affairs has evolved from a support function into one of the most strategically important pillars of the pharmaceutical enterprise. Today, Medical Affairs professionals are expected to interpret complex science, communicate evidence responsibly, engage external experts, identify unmet medical needs, support evidence generation, understand health systems, operate within strict compliance boundaries, and help ensure that the right scientific information reaches the right stakeholders at the right time. That is an extraordinary responsibility. It is also a responsibility that directly affects patients, clinicians, health systems, and public trust.
In my experience working across the pharmaceutical, biotechnology, medical affairs, pharmacy, and healthcare ecosystem, one reality has become increasingly clear: the industry can no longer rely on inconsistent, company specific, informal, or apprenticeship-based approaches to determine whether Medical Affairs professionals possess the competencies required for this work. The stakes are too high, the science is too complex, and the public expectations are too great.
Workforce capability standardization in Medical Affairs should now be viewed as an industry wide issue, not simply a training issue, a talent development issue, or a company level operational concern. It is about whether the pharmaceutical industry can demonstrate that the people representing its science are consistently prepared, ethically grounded, evidence fluent, and capable of supporting better health outcomes.
The need is urgent because the role of Medical Affairs has changed dramatically. Pharmaceutical innovation is no longer limited to relatively straightforward small molecule therapies. The industry is now advancing cell and gene therapies, immunotherapies, precision medicines, rare disease treatments, complex biologics, digital health tools, companion diagnostics, and AI enabled evidence platforms. These innovations require a different level of scientific judgment. The ability to repeat a label or summarize a clinical trial is not enough. Medical Affairs professionals must be able to interpret evidence quality, understand real world data, explain uncertainty, respond to sophisticated clinical questions, and engage in scientific exchange without crossing ethical or regulatory lines.
This is especially true for Medical Science Liaisons, who often serve as the field based scientific face of a company. MSLs interact with healthcare professionals, researchers, academic centers, integrated delivery networks, payers, and other stakeholders who are themselves under pressure to make better decisions with more complex information. When MSL capabilities vary widely, the quality of scientific exchange can vary as well. That variation is not a minor internal inefficiency. It can influence how evidence is understood, how unmet needs are communicated, how clinical insights are gathered, and how trust is built or lost.
Other parts of healthcare have long recognized the importance of standardization. Physicians, pharmacists, nurses, quality professionals, and many other healthcare roles operate within defined education, competency, licensure, certification, or credentialing frameworks. These mechanisms do not guarantee perfection, but they create a shared baseline. They signal that certain knowledge and skills are not optional. They also give employers, regulators, patients, and society a clearer basis for trust.
Medical Affairs should be held to a similarly serious standard. The industry does not need standardization because professionals lack dedication. In fact, most Medical Affairs professionals are deeply committed to science and patients. The problem is that dedication alone is not a reliable system. In high stakes fields, society does not depend only on individual motivation. It builds standards, validates competence, reinforces ethical norms, and measures readiness.
This matters because Medical Affairs sits at a critical intersection between science, industry, healthcare delivery, and patient care. The function does not prescribe medicines, approve products, or replace clinical judgment. However, it plays a major role in how scientific knowledge moves through the healthcare ecosystem. In that sense, Medical Affairs is part of the knowledge infrastructure of modern medicine. If that infrastructure is inconsistent, the consequences extend beyond any single company.
The broader societal argument is straightforward. Better informed healthcare professionals make better decisions. Better scientific exchange supports more appropriate use of therapies. Better insight generation can help companies understand real world barriers and unmet needs. Better ethical judgment reduces the risk of misinformation, promotional overreach, and erosion of trust. Better Medical Affairs capability ultimately supports a healthcare environment in which patients benefit from innovation more safely, appropriately, and equitably.
This is particularly important at a time when public trust in institutions is fragile. The pharmaceutical industry operates in an environment where misinformation spreads quickly, scientific uncertainty is often misunderstood, and commercial motives are frequently scrutinized. Medical Affairs has a unique opportunity to help rebuild and sustain trust, but only if it is clearly differentiated by scientific rigor, professional integrity, and consistent competence.
A standardized competency framework through credible certification can help establish that differentiation. Certification, when properly designed, is not merely a badge or a résumé enhancer. It is a mechanism for defining what good looks like. It creates a common language for the profession. It clarifies expectations for both entry level professionals, experienced MSLs, Medical Directors, hiring managers, learning and development teams, and industry leaders. It can also help reduce variability across companies, geographies, therapeutic areas, and career pathways.
Importantly, certification should not be understood as a substitute for company training. Company training is essential. Every organization must educate its teams on products, pipelines, therapeutic strategies, compliance policies, internal processes, and culture. But company training alone is not enough because it is often built around internal priorities. The industry also needs a portable, external, profession level standard that defines core competencies independent of one employer.
That distinction is critical. A company can train an MSL on its products. A standardized certification can assess whether that MSL understands the broader professional responsibilities of the role: scientific communication, evidence based medicine, clinical trial interpretation, compliance principles, stakeholder engagement, insight generation, health economics, patient centricity, ethics, and the evolving structure of healthcare. Both are necessary. One prepares the employee for the company. The other helps prepare the professional for the responsibilities of the field.
The timing also matters because talent pathways into Medical Affairs are more diverse than ever. Professionals enter from pharmacy, medicine, nursing, PhD research, industry fellowships, clinical practice, academia, consulting, and other backgrounds. This diversity is a strength, but it also creates variability. A PharmD may bring clinical and medication expertise. A PhD may bring deep research training. A physician may bring diagnostic and patient care experience. A nurse may bring care coordination and patient journey insight. None of these backgrounds automatically ensures readiness for the unique responsibilities of Medical Affairs.
Standardization can help create fairness and clarity in that environment. It can give aspiring professionals a transparent roadmap. It can help employers evaluate candidates more consistently. It can reduce overreliance on informal networks or vague assumptions about credentials. It can also support diversity by making expectations more explicit and less dependent on who had access to insider knowledge about the profession.
There is also a business case, but the business case should not be the primary argument. Companies benefit when their Medical Affairs teams are more capable, credible, and consistent. Better prepared teams can engage more effectively, generate higher quality insights, reduce compliance risk, and improve cross functional collaboration. However, the more important point is that pharmaceutical companies have a societal obligation to ensure that the people communicating their science meet a recognized standard of competence.
The industry already accepts this principle in other areas. Clinical trials require trained investigators, defined protocols, ethical review, and regulatory oversight. Manufacturing requires quality systems and validated processes. Pharmacovigilance requires disciplined reporting and risk management. Commercial activities are governed by extensive compliance expectations. Medical Affairs should not be an exception. If anything, because Medical Affairs operates in the space where science is interpreted and exchanged, the need for competency standardization is even more important.
The rapid growth of artificial intelligence makes the issue even more urgent. AI tools can accelerate literature review, summarize data, personalize learning, analyze insights, and support field planning. But AI also increases the need for human judgment. A Medical Affairs professional must know how to evaluate the quality of AI generated outputs, recognize bias, protect confidentiality, avoid unsupported claims, and apply scientific reasoning. Technology does not eliminate the need for competence. It raises the standard for it.
A credible certification standard should also evolve as the profession evolves. It should not be static. The Medical Affairs of the next decade will require fluency in real world evidence, digital engagement, health equity, patient engagement, value based care, data governance, and global regulatory expectations. Standardization should therefore create a foundation while allowing continuous renewal. The goal is not to freeze the profession in place. The goal is to ensure that the profession advances responsibly.
Some may argue that standardization could limit innovation or reduce flexibility. That concern is understandable but misplaced. Good standards do not prevent excellence. They establish a floor, not a ceiling. They define minimum expectations while still allowing companies and individuals to exceed them. In fact, standardization can accelerate innovation by ensuring that professionals share a baseline understanding and can collaborate more effectively across organizations.
Others may argue that Medical Affairs roles vary too much across companies and therapeutic areas to support a common standard. But variation exists in many professions that still maintain core competencies. A cardiologist, oncologist, and psychiatrist practice differently, yet medicine has shared professional foundations. A hospital pharmacist and an industry pharmacist may work in different settings, yet pharmacy has common educational and ethical expectations. Medical Affairs can also define core capabilities while allowing specialization.
The pharmaceutical industry is entering an era in which scientific complexity, public scrutiny, regulatory expectations, and patient need are all increasing at the same time. In that environment, workforce capability standardization is not optional. It is part of responsible industry stewardship.
The ultimate purpose of pharmaceutical innovation is not only to discover, develop, and launch products. It is to improve human health. That purpose cannot be fulfilled by science alone. It requires capable people who can translate science into meaningful, ethical, and useful exchange with the healthcare community. It requires professionals who understand not only data, but also the responsibilities that come with representing data.
For Medical Affairs and Medical Science Liaisons, standardized competency through certification is one of the most practical ways to strengthen that professional foundation. It can help the industry move from variable readiness to shared expectations, from informal assumptions to validated competence, and from company specific training to profession level accountability.
This is not about promoting one organization or one credential as the answer. It is about recognizing a larger truth: the pharmaceutical industry needs a common standard for the professionals entrusted with scientific exchange. Patients, healthcare providers, companies, regulators, and society all benefit when Medical Affairs is competent, ethical, consistent, and prepared for the future.
In the end, workforce capability standardization is not merely about professional development. It is about trust. It is about patient safety. It is about the responsible use of innovation. It is about ensuring that the people who stand between complex science and real world healthcare decisions are prepared to serve that role with excellence. Indeed, the pharmaceutical industry should embrace competency standardization in Medical Affairs not as a competitive advantage, but as a shared responsibility.
Author Bio
William Soliman, PhD, BCMAS, is the Founder/CEO of the Accreditation Council for Medical Affairs (ACMA), the company that accredits, certifies and trains the pharma field force. He’s also the Founder/CIO of White Manna Capital Partners, a long/short public equities healthcare, biotech, and pharma hedge fund. Dr. Soliman is a former senior pharmaceutical industry executive with deep experience in medical affairs, pharmaceutical industry commercialization, reimbursement and innovative capital allocation strategies in healthcare. He is widely recognized for advancing the industry standard for the Medical Affairs and MSL profession through the establishment of the Board Certified Medical Affairs Specialist (BCMAS) program.
